Clinical Trial Update: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ICP-490 for relapsed or refractory non-Hodgkin lymphoma; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• ICP-490

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING